The Evolution and Management of Migraine Recurrence Beyond 24 Hours

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2010 by Rutgers, The State University of New Jersey.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Endo Pharmaceuticals
Information provided by:
Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier:
NCT00754611
First received: September 9, 2008
Last updated: February 3, 2010
Last verified: February 2010

September 9, 2008
February 3, 2010
December 2008
December 2010   (final data collection date for primary outcome measure)
Primary efficacy outcomes will be sustained pain free response between 4 and 72 hours after initial abortive medication dosing (lack of recurrence over 72 hours) [ Time Frame: 4 to 72 hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00754611 on ClinicalTrials.gov Archive Site
  • Pain response and pain free data [ Time Frame: 30 minutes, 1,2,4,24,48,and 72 hours ] [ Designated as safety issue: No ]
  • Rate of recurrence, time of recurrence, time to re-dosing [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
  • Rate of recurrence among multiple attacks per subject [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
The Evolution and Management of Migraine Recurrence Beyond 24 Hours
The Evolution and Management of Migraine Recurrence Beyond 24 Hours: A Prospective Study of Tertiary Care Center Patients

What is the course of migraine headache recurrence, how is it managed, what characteristics are associated with it, and how does it influence patient satisfaction with treatment?

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Patients at the University Headache Center, aged 18 or older, with a diagnosis of migraine with and/or without aura as defined by ICHD-II criteria

Migraine
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
100
December 2010
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female and male patients at University Headache Center with > 6 month diagnosis of migraine with and/or without aura (ICHD-II)
  • Greater than or equal to 18 years old

Exclusion Criteria:

  • Greater than 15 days/month total headache days
  • Analgesic use greater than 15 days/month (other than aspirin less than or equal to 325mg/d)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00754611
EN4162008
No
Loretta Mueller, D.O., University of Medicine and Dentistry of New Jersey
University of Medicine and Dentistry of New Jersey
Endo Pharmaceuticals
Principal Investigator: Loretta Mueller, DO Rutgers, The State University of New Jersey
Rutgers, The State University of New Jersey
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP